Skip to main content
Monday 16 June 2025
BlueSky linkedin youtube rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • Axtria Ignite 2025
    • LS Industry Report 2025
    • Frontiers Health 2024
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
BlueSky linkedin rss
Sign in

For general queries

Email: [email protected]

 

 

How can we help?

For advertising queries please email [email protected] or for further information visit our Advertise page

For editorial queries please email [email protected] or for further information visit our Contribute page

 

Follow us

Facebook   Twitter   YouTube   LinkedIn   RSS
 
 

News
After rebuffing Biogen, Sage pairs off with Supernus

After rebuffing Biogen, Sage pairs off with Supernus

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

R&D
Deep Dive's research and development 2025 edition out now banner

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research. 

R&D
Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Oncology
pharmaphorum podcast Episode 184a

Treating primary bone cancer: The potential of listeria-base...

In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.

Oncology
Life Sciences Industry Report - Part 5 feature image

Life Sciences Industry Report - Oncology

Developments in the oncology space in 2024 brought hope to both industry and patients.

Digital
New Jersey skyline
Partner Content

Axtria Ignite 2025: Leading in an Agentic Era

Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This

Patients
Operationalize: Expanded Access Programs comes to the West Coast!
Partner Content

Operationalize: Expanded Access Programs comes to the West C...

Improving Global Access to Life-Changing Therapeutics...

Editor's Picks

  1. US lawmakers seek ban on DTC advertising
  2. Novo Nordisk teams up with NVIDIA on AI models
  3. AZ taps Chinese firm CSPC's AI acumen in $5.2bn+ alliance
  4. UK follows through on doubling of statutory scheme rate
  5. Makary, Prasad set out their vision for the FDA
News
After rebuffing Biogen, Sage pairs off with Supernus

After rebuffing Biogen, Sage pairs off with Supernus

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.

Market Access
pharmaphorum podcast Episode 178a - Sandra Anderson and Chris Williams, Cencora

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • ASCO 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
OSZAR »